“If they're smart on a CD10 EUA they'll buy ever
Post# of 148168
The CD10 data isn’t robust enough, and CYDY doesn’t have a large enough bribe, to get leronlimab approved in the Phillippines on the CD10 data alone or in combination with the EIND data. Unless of course NP promises a bribe based on revenues from the sale and not on the current cash on hand.
I don’t see why CYDY can’t wait until the full data from 390 patients is analyzed to file in the Phillippines. It just makes more sense and I’d expect approval to be much more likely at that time.